While bumetanide is a promising therapy for neurological disorders involving an E/I imbalance, this approach needs to be refined to enhance brain penetration and selectively target NKCC1 to enhance efficacy and reduce potential peripheral side effects [113]. This evidence concerns the gene SLC12A2 and nervous system disorder.